000141710 001__ 141710
000141710 005__ 20240229111724.0
000141710 0247_ $$2doi$$a10.2337/db17-1268
000141710 0247_ $$2pmid$$apmid:29523632
000141710 0247_ $$2ISSN$$a0012-1797
000141710 0247_ $$2ISSN$$a1939-327X
000141710 0247_ $$2altmetric$$aaltmetric:34157249
000141710 037__ $$aDKFZ-2018-01981
000141710 041__ $$aeng
000141710 082__ $$a610
000141710 1001_ $$00000-0002-7496-3665$$aKröger, Janine$$b0
000141710 245__ $$aCirculating Fetuin-A and Risk of Type 2 Diabetes: A Mendelian Randomization Analysis.
000141710 260__ $$aAlexandria, Va$$bAssoc.$$c2018
000141710 3367_ $$2DRIVER$$aarticle
000141710 3367_ $$2DataCite$$aOutput Types/Journal article
000141710 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1550485204_708
000141710 3367_ $$2BibTeX$$aARTICLE
000141710 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000141710 3367_ $$00$$2EndNote$$aJournal Article
000141710 520__ $$aFetuin-A, a hepatic-origin protein, is strongly positively associated with risk of type 2 diabetes in human observational studies, but it is unknown whether this association is causal. We aimed to study the potential causal relation of circulating fetuin-A to risk of type 2 diabetes in a Mendelian randomization study with single nucleotide polymorphisms located in the fetuin-A-encoding AHSG gene. We used data from eight European countries of the European Prospective Investigation into Cancer and Nutrition (EPIC)-InterAct case-cohort study including 10,020 incident cases. Plasma fetuin-A concentration was measured in a subset of 965 subcohort participants and 654 case subjects. A genetic score of the AHSG single nucleotide polymorphisms was strongly associated with fetuin-A (28% explained variation). Using the genetic score as instrumental variable of fetuin-A, we observed no significant association of a 50 µg/mL higher fetuin-A concentration with diabetes risk (hazard ratio 1.02 [95% CI 0.97, 1.07]). Combining our results with those from the DIAbetes Genetics Replication And Meta-analysis (DIAGRAM) consortium (12,171 case subjects) also did not suggest a clear significant relation of fetuin-A with diabetes risk. In conclusion, although there is mechanistic evidence for an effect of fetuin-A on insulin sensitivity and secretion, this study does not support a strong, relevant relationship between circulating fetuin-A and diabetes risk in the general population.
000141710 536__ $$0G:(DE-HGF)POF3-323$$a323 - Metabolic Dysfunction as Risk Factor (POF3-323)$$cPOF3-323$$fPOF III$$x0
000141710 588__ $$aDataset connected to CrossRef, PubMed,
000141710 650_7 $$2NLM Chemicals$$aAHSG protein, human
000141710 650_7 $$2NLM Chemicals$$aBiomarkers
000141710 650_7 $$2NLM Chemicals$$aalpha-2-HS-Glycoprotein
000141710 7001_ $$aMeidtner, Karina$$b1
000141710 7001_ $$00000-0002-2186-9595$$aStefan, Norbert$$b2
000141710 7001_ $$aGuevara, Marcela$$b3
000141710 7001_ $$aKerrison, Nicola D$$b4
000141710 7001_ $$aArdanaz, Eva$$b5
000141710 7001_ $$aAune, Dagfinn$$b6
000141710 7001_ $$aBoeing, Heiner$$b7
000141710 7001_ $$aDorronsoro, Miren$$b8
000141710 7001_ $$aDow, Courtney$$b9
000141710 7001_ $$00000-0001-5033-5966$$aFagherazzi, Guy$$b10
000141710 7001_ $$00000-0002-0520-7604$$aFranks, Paul W$$b11
000141710 7001_ $$aFreisling, Heinz$$b12
000141710 7001_ $$aGunter, Marc J$$b13
000141710 7001_ $$aHuerta, José María$$b14
000141710 7001_ $$0P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a$$aKaaks, Rudolf$$b15$$udkfz
000141710 7001_ $$aKey, Timothy J$$b16
000141710 7001_ $$aKhaw, Kay Tee$$b17
000141710 7001_ $$aKrogh, Vittorio$$b18
000141710 7001_ $$0P:(DE-He78)0907a10ba1dc8f53f04907f54f6fdcfe$$aKühn, Tilman$$b19$$udkfz
000141710 7001_ $$aMancini, Francesca Romana$$b20
000141710 7001_ $$aMattiello, Amalia$$b21
000141710 7001_ $$aNilsson, Peter M$$b22
000141710 7001_ $$aOlsen, Anja$$b23
000141710 7001_ $$aOvervad, Kim$$b24
000141710 7001_ $$aPalli, Domenico$$b25
000141710 7001_ $$aQuirós, J Ramón$$b26
000141710 7001_ $$aRolandsson, Olov$$b27
000141710 7001_ $$aSacerdote, Carlotta$$b28
000141710 7001_ $$aSala, Núria$$b29
000141710 7001_ $$aSalamanca-Fernández, Elena$$b30
000141710 7001_ $$aSluijs, Ivonne$$b31
000141710 7001_ $$aSpijkerman, Annemieke M W$$b32
000141710 7001_ $$aTjonneland, Anne$$b33
000141710 7001_ $$aTsilidis, Konstantinos K$$b34
000141710 7001_ $$aTumino, Rosario$$b35
000141710 7001_ $$avan der Schouw, Yvonne T$$b36
000141710 7001_ $$00000-0002-5041-248X$$aForouhi, Nita G$$b37
000141710 7001_ $$aSharp, Stephen J$$b38
000141710 7001_ $$aLangenberg, Claudia$$b39
000141710 7001_ $$aRiboli, Elio$$b40
000141710 7001_ $$00000-0002-0830-5277$$aSchulze, Matthias B$$b41
000141710 7001_ $$aWareham, Nicholas J$$b42
000141710 773__ $$0PERI:(DE-600)1501252-9$$a10.2337/db17-1268$$gVol. 67, no. 6, p. 1200 - 1205$$n6$$p1200 - 1205$$tDiabetes$$v67$$x1939-327X$$y2018
000141710 909CO $$ooai:inrepo02.dkfz.de:141710$$pVDB
000141710 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a$$aDeutsches Krebsforschungszentrum$$b15$$kDKFZ
000141710 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)0907a10ba1dc8f53f04907f54f6fdcfe$$aDeutsches Krebsforschungszentrum$$b19$$kDKFZ
000141710 9131_ $$0G:(DE-HGF)POF3-323$$1G:(DE-HGF)POF3-320$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lHerz-Kreislauf-Stoffwechselerkrankungen$$vMetabolic Dysfunction as Risk Factor$$x0
000141710 9141_ $$y2018
000141710 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bDIABETES : 2017
000141710 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000141710 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000141710 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000141710 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central
000141710 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000141710 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000141710 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000141710 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000141710 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000141710 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000141710 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000141710 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000141710 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000141710 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bDIABETES : 2017
000141710 9201_ $$0I:(DE-He78)C020-20160331$$kC020$$lEpidemiologie von Krebserkrankungen$$x0
000141710 980__ $$ajournal
000141710 980__ $$aVDB
000141710 980__ $$aI:(DE-He78)C020-20160331
000141710 980__ $$aUNRESTRICTED